Search results for " Polypharmacy"

showing 10 items of 22 documents

Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study.

2011

BACKGROUND: Although the association between multimorbidity and polypharmacy has been clearly documented, no study has analyzed whether or not specific combinations of diseases influence the prescription of polypharmacy in older persons. We assessed which clusters of diseases are associated with polypharmacy in acute-care elderly in-patients. METHODS: This cross-sectional study was held in 38 Italian internal medicine and geriatric wards participating in the Registro Politerapie SIMI (REPOSI) study during 2008. The study sample included 1155 in-patients aged 65 years or older. Clusters of diseases, defined as two or more co-occurring specific chronic diseases, were identified using the odds…

---Lung DiseasesMaleSettore MED/09 - Medicina InternaCross-sectional studyGastrointestinal DiseasesComorbidityRisk FactorsNeoplasmsPrevalenceCluster AnalysisHospitalized elderlyclustersGeriatricsAged 80 and overCOPDREPOSISettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheHospitalization---; clusters; polypharmacy; REPOSI; elderlyCardiovascular DiseasesFemalemedicine.medical_specialtyEndocrine System DiseaseselderlyCluster of diseasesInternal medicineDiabetes mellitusmedicineDiabetes MellitusInternal MedicineMultimorbidityHumansCluster of diseases; Hospitalized elderly; PolypharmacyAgedPolypharmacybusiness.industryPolypharmacy Cluster of diseases Hospitalized elderlyOdds ratiomedicine.diseaseComorbidityCross-Sectional StudiesLogistic ModelsGeriatricsPhysical therapyPolypharmacyDementiaMorbiditybusinessEuropean journal of internal medicine
researchProduct

Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study

2019

<b><i>Objective:</i></b> Older people approaching the end of life are at a high risk for adverse drug reactions. Approaching the end of life should change the therapeutic aims, triggering a reduction in the number of drugs.<b><i></i></b>The main aim of this study is to describe the preventive and symptomatic drug treatments prescribed to patients discharged with a limited life expectancy from internal medicine and geriatric wards. The secondary aim was to describe the potentially severe drug-drug interactions (DDI). <b><i>Materials and Methods:</i></b> We analyzed Registry of Polytherapies Societa Italiana di Medicina I…

0301 basic medicineDrugMalemedicine.medical_specialtyDeprescriptions020205 medical informaticsDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectElderly; End of life; Limited life expectancy; Polypharmacy; Symptomatic medications; Aged 80 and over; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Male; Polypharmacy; Deprescriptions; Life Expectancy; Patient DischargeSocio-culturale02 engineering and technology03 medical and health sciencesElderly · End of life · Limited life expectancy · Polypharmacy · Symptomatic medicationsPharmacotherapyDeprescriptionsLife ExpectancyElderlySymptomatic medications0202 electrical engineering electronic engineering information engineeringmedicine80 and overHumansLS4_4Medical prescriptionElderly; End of life; Limited life expectancy; Polypharmacy; Symptomatic medicationsmedia_commonAgedPolypharmacyAged 80 and overOriginal Paperbusiness.industryGeneral MedicineElderly End-of-life Limited life expectancy Polypharmacy Preventing medications Symptomatic medicationsElderly End of life Limited life expectancy Polypharmacy Symptomatic medicationsPatient DischargeClonidineLimited life expectancyItalyEmergency medicineEnd of lifeLife expectancyPolypharmacyFemale030101 anatomy & morphologyDeprescribingbusinessmedicine.drugSymptomatic medication
researchProduct

Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study.

2016

Aims.In recent years several warnings have been issued by regulatory authorities on the risk of electrocardiogram abnormalities in individuals exposed to psychotropic drugs. As a consequence of these warnings, monitoring of the QT interval corrected for heart rate (QTc) has become increasingly common. This study was conducted to measure the frequency of QTc prolongation in unselected psychiatric patients, and to document the associated factors using a cross-sectional approach.Method.The study was carried out in 35 Italian psychiatric services that are part of the STAR (Servizi Territoriali Associati per la Ricerca) Network, a research group established to produce scientific knowledge by col…

AdultMalemedicine.medical_specialtyPsychotropic drugsEpidemiologymedicine.medical_treatmentLong QT syndromeAntidepressantDrug overdoseAdverse effectQT intervalAntipsychotic03 medical and health sciencesElectrocardiography0302 clinical medicineRisk FactorsPsychotropic drugmedicinePrevalenceHumanscardiovascular diseasesAntipsychoticAdverse effectPsychiatrySettore MED/25 - PsichiatriaPolypharmacybusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Epidemiology; Public Health; Environmental and Occupational Health; Psychiatry and Mental HealthOriginal Articlesmedicine.diseaseAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Epidemiology; Public Health Environmental and Occupational Health; Psychiatry and Mental Health030227 psychiatrySubstance abuseLong QT SyndromeCross-Sectional StudiesItalyPsychiatry and Mental HealthPolypharmacyAripiprazoleFemalePublic HealthbusinessAntidepressant; adverse effect; antipsychotic; psychotropic drugsAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Adult; Antipsychotic Agents; Cross-Sectional Studies; Electrocardiography; Female; Humans; Italy; Long QT Syndrome; Male; Prevalence; Risk Factors; Polypharmacy; Epidemiology; Public Health Environmental and Occupational Health; Psychiatry and Mental Health030217 neurology & neurosurgerymedicine.drugAntipsychotic AgentsEpidemiology and psychiatric sciences
researchProduct

Multimorbidity and polypharmacy in the elderly: Lessons from REPOSI

2014

none 10 no The dramatic demographic changes that are occurring in the third millennium are modifying the mission of generalist professionals such as primary care physicians and internists. Multiple chronic diseases and the related prescription of multiple medications are becoming typical problems and present many challenges. Unfortunately, the available evidence regarding the efficacy of medications has been generated by clinical trials involving patients completely different from those currently admitted to internal medicine: much younger, affected by a single disease and managed in a highly controlled research environment. Because only registries can provide information on drug effectiven…

Adverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Aged; Aged; 80 and over; Female; Humans; Internal Medicine; Italy; Male; Registries; Societies; Medical; Comorbidity; Geriatrics; Polypharmacy; Internal Medicine; Emergency MedicineMalemedicine.medical_specialtyAgingmedia_common.quotation_subjectDrug prescriptionMEDLINEAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Aged; Aged 80 and over; Female; Humans; Internal Medicine; Italy; Male; Registries; Societies Medical; Comorbidity; Geriatrics; Polypharmacy; Internal Medicine; Emergency MedicineDiseaseComorbidityAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; PolypharmacyelderlyAdverse drug effectsPromotion (rank)MedicalmedicineAdverse drug effect80 and overInternal MedicineHumansRegistriesMedical prescriptionmedia_commonAgedGeriatricsPolypharmacyAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Emergency Medicine; Internal MedicineMultimorbidity Polypharmacy Aging Drug prescription Multidimensional evaluation Adverse drug effectsMultidimensional evaluationbusiness.industrySettore MED/09 - MEDICINA INTERNAMultimorbiditymedicine.diseaseComorbidityelderly multimorbidity polypharmacyClinical trialItalyGeriatricsFamily medicinePolypharmacyEmergency MedicineFemaleMedical emergencyAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Internal Medicine; Emergency MedicinebusinessSocietiesmultimorbidity; polypharmacy; aging; drug prescription; multidimensional evaluation; adverse drug effectsMultimorbidity; Polypharmacy; Aging; Drug prescription; Multidimensional evaluation
researchProduct

Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA.

2017

The Strategic Implementation Plan of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) proposed six Action Groups. After almost three years of activity, many achievements have been obtained through commitments or collaborative work of the Action Groups. However, they have often worked in silos and, consequently, synergies between Action Groups have been proposed to strengthen the triple win of the EIP on AHA. The paper presents the methodology and current status of the Task Force on EIP on AHA synergies. Synergies are in line with the Action Groups' new Renovated Action Plan (2016-2018) to ensure that their future objectives are coherent and fully connected. The …

AgingProcess managementGeriatrics & GerontologyEuropean Innovation Partnership on Active and Healthy Ageing polypharmacy education falls frailty integrated care citizen empowerment chronic respiratory diseasesHealth BehaviorChronic respiratory diseasesPARTNERSHIPCoaching[SHS]Humanities and Social Sciences0302 clinical medicineSurveys and Questionnaires80 and overMedicineCooperative BehaviorComputingMilieux_MISCELLANEOUSInterventionsmedia_commonintegrated careAged 80 and over:Enginyeria biomèdica [Àrees temàtiques de la UPC]Multiple Chronic ConditionOrganizational Innovation3. Good healthCHRONIC RESPIRATORY-DISEASESHealthAction planGeneral partnershipFallsHEALTHPartnershipINTERVENTIONSHumanmedia_common.quotation_subjectfallFrail ElderlyEuropean Continental Ancestry GroupBioengineeringWhite PeopleEducation03 medical and health sciencesEUROPEAN-UNIONActive and Healthy Ageingmedia_common.cataloged_instanceHumansBioenginyeriaEuropean unionAgedScience & TechnologyNutrition & DieteticsPreventionPREVENTIONCitizen empowerment030228 respiratory systemAction (philosophy)European Innovation Partnership on Active and Healthy Ageing; polypharmacy; education; falls; frailty; integrated care; citizen empowerment; chronic respiratory diseases; Accidental Falls; Aged; Aged 80 and over; Chronic Disease; Cooperative Behavior; Europe; Frail Elderly; Humans; Multiple Chronic Conditions; Organizational Innovation; Polypharmacy; Surveys and Questionnaires; Aging; European Continental Ancestry Group; Health BehaviorGeriatrics and GerontologyGerontologySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]OPERATIONAL DEFINITIONEMPOWERMENTMedicine (miscellaneous)Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and GerontologyChronic respiratory-diseasesAllergic rhinitisQUALITY-OF-LIFEEuropean-UnionNutrition and DieteticSurveys and Questionnaire030212 general & internal medicineMultiple Chronic ConditionsEmpowermenteducationNutrition and DieteticsFrailtyAccidental FallIntegrated careALLERGIC RHINITISEuropeSettore MED/42EmpowermentLife Sciences & BiomedicinefrailtyEuropean Innovation Partnership on Active and Healthy AgeingJournal ArticleMETIS-318216IR-101708Responsible Research and Innovationbusiness.industrychronic respiratory diseaseIntegrated careOperational definition3121 General medicine internal medicine and other clinical medicineChronic DiseasePolypharmacycitizen empowermentAccidental Fallschronic respiratory diseases; citizen empowerment; education; European Innovation Partnership on Active and Healthy Ageing; falls; frailty; integrated care; polypharmacy; Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and GerontologyQuality-of-lifebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe journal of nutrition, healthaging
researchProduct

Italian guidelines on management of persons with multimorbidity and polypharmacy

2022

AbstractMultimorbidity and polypharmacy are emerging health priorities and the care of persons with these conditions is complex and challenging. The aim of the present guidelines is to develop recommendations for the clinical management of persons with multimorbidity and/or polypharmacy and to provide evidence-based guidance to improve their quality of care. The recommendations have been produced in keeping with the Grading of Recommendations Assessment, Development and Evaluation (GRADE). Overall, 14 recommendations were issued, focusing on 4 thematic areas: (1.) General Principles; (2.) target population for an individualized approach to care; (3.) individualized care of patients with mul…

Deprescribing; Frailty; Models of care; Multimorbidity; Patient-centered care; PolypharmacyAgingDeprescribingFrailtyHealth PrioritiesMultimorbidity · Polypharmacy · Frailty · Patient-centered care · Deprescribing · Models of careModels of carePatient-centered carePolypharmacyHumansSocio-culturaleMultimorbidityGeriatrics and Gerontology
researchProduct

Gender difference in drug use in hospitalized elderly patients.

2015

Purpose The aims of this study were to evaluate whether or not there are gender differences in drug use at hospital admission and prescription at discharge and to evaluate the effect of hospitalization on medication patterns in the elderly. Method In-patients aged > 65 years included in the REPOSI registry during a recruitment period of 3 years (2008-2010-2012) were analyzed in order to evaluate drug use at hospital admission and prescription at discharge according to gender. Results A total of 3473 patients, 52% women and 48% men, were considered. Polypharmacy (> 5 drugs) is more frequent in men both at hospital admission and discharge. At hospital discharge, the number of prescripti…

DrugMalePediatricsmedicine.medical_specialtySettore MED/09 - Medicina Internamedia_common.quotation_subjectSocio-culturaleDrug Prescriptionselderly gender polypharmacyElderlyAge groupsDrug PrescriptionHospital dischargeInternal MedicineMedicineHumansMedical prescriptionSex DistributionPrescribed drugsmedia_commonAgedElderly; Gender; Polypharmacy; Internal MedicinePolypharmacyAged 80 and overSex Characteristicsbusiness.industryGenderSex CharacteristicPatient DischargeHospitalizationHospital admissionPolypharmacyFemalebusinessSex characteristicsHumanEuropean journal of internal medicine
researchProduct

The relationship between Polypharmacy and Trajectories of Cognitive Decline in People with Dementia: a large representative cohort study

2019

Polypharmacy, defined through the number of medications prescribed, has been linked to a range of adverse health outcomes in people with dementia. It is however unclear whether a numerical threshold of concurrently prescribed drugs is a suitable predictor for cognitive decline. We aimed to test associations between polypharmacy and both short-term (six months) and long-term (three years) cognitive trajectories in patients with incident dementia. Using data from a large mental health and dementia care database in South London, a cohort of 12,148 patients (mean age = 80.7 years, 61.1% female, mean MMSE = 18.6) clinically diagnosed with dementia was identified. We determined the number of medi…

Male0301 basic medicineGerontologyAgingCognitive declineBiochemistryCohort Studies03 medical and health sciencesCognitionCommunity care0302 clinical medicineEndocrinologyA large representative cohort study.- Experimental gerontology cilt.120 ss.62-67 2019 [Soysal P. Perera G. Isik A. Onder G. Petrovic M. Cherubini A. Maggi S. Shetty H. Molokhia M. Smith L. et al. -The relationship between polypharmacy and trajectories of cognitive decline in people with dementia]mental disordersGeneticsmedicineHumansDementiaCognitive DysfunctionCognitive declineassociations between polypharmacyMolecular BiologyAgedAged 80 and overPolypharmacypeople with dementia.Mini–Mental State Examinationmedicine.diagnostic_testbusiness.industryCognition; Cognitive decline; Community care; Dementia; PolypharmacyCognitionlong-term (three years)Cell BiologyMental Status and Dementia Testsmedicine.diseaseComorbidity030104 developmental biologyCohortPolypharmacyFemaleDementiabusinessshort-term (six months)030217 neurology & neurosurgeryCohort study
researchProduct

Polypharmacy in people with dementia: Associations with adverse health outcomes

2018

Polypharmacy has been linked to higher risks of hospitalisation and death in community samples. It is commonly present in people with dementia but these risks have rarely been studied in this population. We aimed to investigate associations between polypharmacy and emergency department attendance, any and unplanned hospitalisation, and mortality in patients with dementia. Using a large mental health care database in South London, linked to hospitalisation and mortality data, we assembled a retrospective cohort of patients diagnosed with dementia. We ascertained number of medications prescribed at the time of dementia diagnosis and conducted multivariate Cox regression analyses. Of 4668 pati…

MaleAgingmedicine.medical_specialtyDatabases FactualPopulationBiochemistry03 medical and health sciences0302 clinical medicineEndocrinologyRisk FactorsLondonDementia; Emergency department; Hospitalisation; Mortality; Pharmacoepidemiology; PolypharmacyGeneticsmedicineHospitalisationDementiaHumans030212 general & internal medicineMortalityeducationMolecular BiologyAgedRetrospective StudiesPolypharmacyAged 80 and overeducation.field_of_studyProportional hazards modelbusiness.industryEmergency departmentPharmacoepidemiologyHazard ratioAttendanceRetrospective cohort studyCell BiologyEmergency departmentmedicine.diseaseSurvival AnalysisHospitalizationEmergency medicineMultivariate AnalysisPolypharmacyFemaleDementiabusinessEmergency Service Hospital030217 neurology & neurosurgery
researchProduct

Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study

2018

Background: Among rate-control or rhythm-control strategies, there is conflicting evidence as to which is the best management approach for non-valvular atrial fibrillation (AF) in elderly patients. Design: We performed an ancillary analysis from the ‘Registro Politerapie SIMI’ study, enrolling elderly inpatients from internal medicine and geriatric wards. Methods: We considered patients enrolled from 2008 to 2014 with an AF diagnosis at admission, treated with a rate-control-only or rhythm-control-only strategy. Results: Among 1114 patients, 241 (21.6%) were managed with observation only and 122 (11%) were managed with both the rate- and rhythm-control approaches. Of the remaining 751 patie…

MaleAnti-Arrhythmia Agents/therapeutic useantiarrhythmic agentComorbidityAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; Prevalence; Geriatrics and Gerontology; Pharmacology (medical)030204 cardiovascular system & hematologyanticoagulant agentDiabetes Mellitus/drug therapy0302 clinical medicineHeart RateAtrial Fibrillation80 and overOdds RatioPrevalencePharmacology (medical)030212 general & internal medicineLS4_4Aged 80 and overantiarrhythmic agent anticoagulant agent antithrombocytic agent calcium channel blocking agent digoxinHeart Rate/drug effectsDiabetes MellituAtrial fibrillationantithrombocytic agentdigoxinHospitalizationAnti-Arrhythmia AgentFemaleAnti-Arrhythmia AgentsHumanmedicine.medical_specialtySocio-culturale-Geriatrics and Gerontology; Pharmacology (medical)03 medical and health sciencesInternal medicineDiabetes mellitusHeart rateantiarrhythmic agent; anticoagulant agent; antithrombocytic agent; calcium channel blocking agent; digoxinmedicineDiabetes MellitusHumansAgedPolypharmacyHeart Failurebusiness.industryAtrial Fibrillation/drug therapyOdds ratiomedicine.diseaseHeart Failure/drug therapyComorbidityConfidence intervalcalcium channel blocking agentHeart failurePolypharmacyAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; PrevalenceGeriatrics and Gerontologybusiness
researchProduct